Platelets enhance activity of antimycotic substances against non-Aspergillus fumigatus Aspergillus species in vitro

References

• Denning DW. Invasive aspergillosis. Clin Infect Dis 1998; 26: 781–805.
   PubMed Web of Science ®Google Scholar
• Marr KA, Patterson T, Denning DW. Aspergillosis. Pathogenesis, clinical manifestations, and therapy. Infect Dis Clin N Am 2002; 16: 875–894.
   PubMed Web of Science ®Google Scholar
• Lin SJ, Schranz J, Teutsch SM. Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis 2001; 32: 358–366.
   PubMed Web of Science ®Google Scholar
• Garcia-Vidal C, Upton A, Kirby KA, Marr KA. Epidemiology of invasive mold infections in allogenic stem cell transplant recipients: biological risk factors for infections according to time after transplantation. Clin Infect Dis 2008; 47: 1041–1050.
   PubMed Web of Science ®Google Scholar
• Garber G. An overview of fungal infections. Drugs 2001; 61(Suppl. 1): 1–12.
   PubMedGoogle Scholar
• Lass-Flörl C. The changing face of epidemiology of invasive fungal disease in Europe. Mycoses 2009; 52: 197–205.
   PubMed Web of Science ®Google Scholar
• Denning DW. Epidemiology and pathogenesis of systemic fungal infections in the immunocompromised host. J Antimicrob Chemother 1991; 28(Suppl. B): 1–16.
   PubMedGoogle Scholar
• Dagenais TR, Keller NP. Pathogenesis of Aspergillus fumigatus in invasive aspergillosis. Clin Microbiol Rev 2009; 22: 447–465.
   PubMed Web of Science ®Google Scholar
• Jurk K, Kehrel BE. Platelets: physiology and biochemistry. Semin Thromb Hemost 2005; 31: 381–392.
   PubMed Web of Science ®Google Scholar
• Yeaman MR. The role of platelets in antimicrobial host defense. Clin Infect Dis 1997; 25: 951–970.
   PubMed Web of Science ®Google Scholar
• Tang YQ, Yeaman MR, Selsted ME. Antimicrobial peptides from human platelets. Infect Immun 2002; 70: 6524–6533.
   PubMed Web of Science ®Google Scholar
• Fitzgerald JR, Foster TJ, Cox D. The interaction of bacterial pathogens with platelets. Nat Rev Microbiol 2006; 4: 445–457.
   PubMed Web of Science ®Google Scholar
• Perkhofer S, Kehrel BE, von Eiff C, . Human platelets attenuate virulence of Aspergillus spp. via granule dependent mechanisms. J Inf Dis 2008; 198: 1243–1246.
   PubMed Web of Science ®Google Scholar
• Perkhofer S, Kainzner B, Kehrel BE, . Potential antifungal effects of human platelets against Zygomycetes in vitro. J Infect Dis 2009; 200: 1176–1179.
   PubMed Web of Science ®Google Scholar
• Chandrasekar PH, Cutright JL, Manavathu EK. Aspergillus: Rising frequency of clinical isolation and continued susceptibility to antifungal agents, 1994–1999. Diagn Microbiol Infect Dis 2001; 41: 211–214.
   PubMed Web of Science ®Google Scholar
• Bauters T, Buyle F, Peleman R, . Antifungal drugs and rational use of antifungals in treating invasive aspergillosis: the role of the hospital pharmacist. Pharm World Sci 2005; 27: 31–34.
   PubMedGoogle Scholar
• Torres HA, Hachem R, Chemaly RF, . POS: a broad-spectrum triazole antifungal. Lancet Infect Dis 2005; 12: 775–785.
   Google Scholar
• Walsh TJ, Teppler H, Donowitz GR, . CAS versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 2004; 347: 1391–1402.
   Google Scholar
• Dotis J, Simitsopoulou M, Dalakiouridou M, . Effects of lipid formulations of amphotericin B on Activity of human monocytes against Aspergillus fumigatus. Antimicrob Agents Chemother 2006; 50: 868–873.
   PubMed Web of Science ®Google Scholar
• Gil-Lamaignere C, Roilides E, Malokoukou A, . Amphotericin B lipid complex exerts additive antifungal activity in combination with polymorphonuclear leucocytes against Scedosporium prolificans and Scedosporium apiospermum. J Antimicrob Chemother 2002; 50: 1027–1030.
   PubMed Web of Science ®Google Scholar
• Gil-Lamaignere C, Roilides E, Mosquera J, . Antifungal triazoles and polymorphonuclear leukocytes synergize to cause increased hyphal damage to Scedosporium prolificans and Scedosporium apiospermum. Antimicrob Agents Chemother 2002; 46: 2234–2237.
   PubMed Web of Science ®Google Scholar
• Roilides E, Uhlig K, Venzon D, . Enhancement of oxidative response and damage caused by human neutrophils to Aspergillus fumigatus hyphae by granulocyte colony-stimulating factor and gamma interferon. Infect Immun 1993; 61: 1185–1193.
   PubMed Web of Science ®Google Scholar
• Perkhofer S, Trappl K, Nussbaumer W, Dierich MP, Lass-Flörl C. Potential synergistic activity of antimycotic substances in combination with human platelets against Aspergillus fumigatus. J Antimicrob Chemother 2010; 65: 1309–1311.
   PubMedGoogle Scholar
• Lass-Flörl C, Mayr A, Perkhofer S, . Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. Antimicrob Agents Chemother 2008; 52: 3637–3641.
   PubMed Web of Science ®Google Scholar
• Lass-Flörl C, Griff K, Mayr A, . Epidemiology and outcome of infections due to Aspergillus terreus: 10-year single centre experience. Br J Haematol 2005; 131: 201–207.
   PubMed Web of Science ®Google Scholar
• Meletiadis J, Antachopoulos C, Stergiopoulou T, . Differential fungicidal activities of amphotericin B and voriconazole against Aspergillus species determined by microbroth methodology. Antimicrob Agents Chemother 2007; 51: 3329–3337.
   PubMed Web of Science ®Google Scholar
• Clinical and Laboratory Standards Institute/National Committee for Clinical Laboratory Standards. Methods for Dilution Antimicrobial Susceptibility Tests for Filamentous Fungi. Approved Standard M38-A. Wayne, PA: National Committee for Clinical Laboratory Standards, 2007.
   Google Scholar
• Perkhofer S. Niederegger H, Blum G, . Interaction of 5-hydroxytryptamine (serotonin) against Aspergillus spp. in vitro. Int J Antimicrob Agents 2007; 4: 424–429.
   Google Scholar
• Colman RW, Stewart G, Budzynski A, . Thrombosis and haemostasis. Nature 1979; 282: 676–682.
   PubMed Web of Science ®Google Scholar
• Hogan LH, Klein BS, Levitz SM. Virulence factors of medically important fungi. Clin Microbiol Rev 1996; 4: 469–488.
   Google Scholar
• Kamai Y, Chiang LY, Lopes Bezerra LM, . Interaction of Aspergillus fumigatus with vascular endothelial cells. Med Mycol 2006; 44(Suppl. 1): 115–117.
   Google Scholar
• Dannaoui E, Borel E, Persat F, Piens MA, Picot S. Amphotericin B resistance of Aspergillus terreus in a murine model of disseminated aspergillosis. J Med Microbiol 1999; 49: 601–606.
   Google Scholar
• Christin L, Wysong D, Meshulam T, . Human platelets damage Aspergillus fumigatus hyphae and may supplement killing neutrophils. Infect Immun 1998; 66: 1181–1189.
   PubMed Web of Science ®Google Scholar
• Vora S, Chauhan S, Brummer E, . Activity of VOR combined with neutrophils or monocytes against Aspergillus fumigatus: effects of granulocyte colony stimulating factor and granulocyte-macrophage colony stimulating factors. Antimicrob Agents Chemother 1998; 42: 2299–2303.
   PubMed Web of Science ®Google Scholar
• Chiller T, Farrokhshad K, Brummer E, . The interaction of human monocytes, monocyte-derived macrophages and polymorphonuclear neutrophils with CAS (MK-0991), an echinocandin, for antifungal activity against Aspergillus fumigatus. Diagn Microbiol Infect Dis 2001; 39: 99–103.
   PubMed Web of Science ®Google Scholar
• Kaufmann D. Fungal infection in the very low birthweight infant. Curr Opin Infect Dis 2004; 17: 253–259.
   PubMedGoogle Scholar
• Chang FY, Singh N, Gayowski T, . Thrombocytopenia in liver transplant recipients: predictors, impact on fungal infections, and role of endogenous thrombopoetin. Transplantation 2000; 69: 70–79.
   PubMed Web of Science ®Google Scholar
• Guida L, Kunig AM, Leef KH, . Platelet count and sepsis in very low birth weight neonates: is there an organism-specific response? Pediatrics 2003; 111: 1411–1415.
   PubMed Web of Science ®Google Scholar